PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy
J Liu, Z Chen, Y Li, W Zhao, JB Wu… - Frontiers in …, 2021 - frontiersin.org
Programmed death protein 1 (PD1) is a common immunosuppressive member on the
surface of T cells and plays an imperative part in downregulating the immune system and …
surface of T cells and plays an imperative part in downregulating the immune system and …
Harnessing big data to characterize immune-related adverse events
Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
From real-world electronic health record data to real-world results using artificial intelligence
With the worldwide digitalisation of medical records, electronic health records (EHRs) have
become an increasingly important source of real-world data (RWD). RWD can complement …
become an increasingly important source of real-world data (RWD). RWD can complement …
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
F Yang, C Shay, M Abousaud, C Tang, Y Li… - Journal of Experimental …, 2023 - Springer
Background Immune-related adverse events (irAEs) are a common phenomenon in cancer
patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of …
patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of …
[HTML][HTML] Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
Background Immune checkpoint inhibitor (ICI)-related pneumonitis is the most frequent fatal
immune-related adverse event associated with programmed cell death protein …
immune-related adverse event associated with programmed cell death protein …
Applications of model-based meta-analysis in drug development
Abstract Model-based meta-analysis (MBMA) is a quantitative approach that leverages
published summary data along with internal data and can be applied to inform key drug …
published summary data along with internal data and can be applied to inform key drug …
Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events
Over the past decade, the use of immune checkpoint inhibitors (ICI) has expanded across a
wide spectrum of oncology indications. Immune-related adverse events (irAE) from ICIs …
wide spectrum of oncology indications. Immune-related adverse events (irAE) from ICIs …
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
Background Immune-related adverse events (IRAE) pose a significant diagnostic and
therapeutic challenge in patients treated with immune-oncology (IO) drugs. IRAEs have …
therapeutic challenge in patients treated with immune-oncology (IO) drugs. IRAEs have …
Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes
R Matsukane, K Suetsugu, K Hata, K Matsuda… - International Journal of …, 2023 - Springer
Background Recent advances in immune-checkpoint inhibitors (ICIs) have highlighted the
need for effective management of immune-related adverse events (irAEs). This study aimed …
need for effective management of immune-related adverse events (irAEs). This study aimed …
Screening and identification of an anti-PD-1 nanobody with antitumor activity
Y Zhang, S Yang, D Jiang, Y Li, S Ma, L Wang… - Bioscience …, 2023 - portlandpress.com
Blocking of programmed death protein 1 (PD-1) or its ligand PD-L1 with corresponding
antibody to enhance T-cell response and mediate antitumor activity has been successfully …
antibody to enhance T-cell response and mediate antitumor activity has been successfully …